Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2008 Oct;69(5):459–465. doi: 10.1016/j.curtheres.2008.10.003

The effects of montelukast on random pattern skin flap survival: An experimental study in rats

Kaan Gideroglu 1,a, Fahrettin Yilmaz 2, Fadullah Aksoy 3, Guler Bugdayci 4, Husamettin Cakici 5, Onur Hapa 6
PMCID: PMC3969934  PMID: 24692820

Abstract

Background: A variety of methods to improve skin flap survival, including the use of pharmacologic agents, have been intensively investigated. Decreasing neutrophil-mediated inflammation and tissue injury has been reported to be effective in improving flap survival. Montelukast is a selective reversible cysteinyl leukotriene receptor-1 antagonist that has been found to have protective effects against renal ischemia reperfusion injury and burn-induced oxidative injury of the skin in rats. However, its effects on skin flap survival have not been previously reported.

Objective: The aim of this study was to investigate the effects of montelukast on neutrophil-mediated random pattern skin flap survival.

Methods: Male Sprague-Dawley rats weighing 230 to 250 g were randomly divided into 2 groups—the montelukast-treated group and the control group. Caudally based rectangular random pattern skin flaps 3 × 9 cm were elevated on the backs of the rats. The flaps were sutured into their original places. In the montelukast group, 1 mL of solution containing 10 mg/kg montelukast was administered intraperitoneally (IP) 30 minutes before surgery and then daily for 6 days. In the control group, 1 mL of saline was administered IP 30 minutes before surgery and then daily for 6 days. To observe the effects of montelukast, myeloperoxidase (MPO) activity, an index of tissue neutrophil infiltration, was measured from extracted skin tissue 12 hours after flap elevation. Flap viability was evaluated 7 days after surgery by measuring necrotic flap area and total flap area.

Results: Sixteen rats (mean [SD] weight, 240.6 [6.6] g) were equally divided between the 2 groups. All rats survived throughout the study period. Mean (SD) MPO activity in flap tissue was significantly lower in the montelukast group than in the control group (14.57 [2.33] vs 21.28 [4.86] U/g protein; P = 0.005). The percentage of necrotic flap area was significantly lower in the montelukast group than in the control group (17.17 [7.95] vs 37.51 [10.72]; P = 0.001).

Conclusion: This small, experimental, in vivo animal study found that montelukast was associated with both lower MPO activity and a lower percentage of necrotic random pattern skin flap area. Future studies are needed to clarify these findings.

Key Words: montelukast, skin flap survival, necrosis

Full Text

The Full Text of this article is available as a PDF (643.9 KB).

References

  • 1.Törkvist L, Löfberg R, Raud J, Thorlacius H. Heparin protects against skin flap necrosis: Relationship to neutrophil recruitment and anti-coagulant activity. Inflamm Res. 2004;53:1–3. doi: 10.1007/s00011-003-1218-0. [DOI] [PubMed] [Google Scholar]
  • 2.Cetin C, Köse AA, Aral E. Protective effect of fucoidin (a neutrophil rolling inhibitor) on ischemia reperfusion injury: Experimental study in rat epigastric island flaps. Ann Plast Surg. 2001;47:540–546. doi: 10.1097/00000637-200111000-00012. [DOI] [PubMed] [Google Scholar]
  • 3.Gute DC, Ishida T, Yarimizu K, Korthuis RJ. Inflammatory responses to ischemia and reperfusion in skeletal muscle. Mol Cell Biochem. 1998;179:169–187. doi: 10.1023/a:1006832207864. [DOI] [PubMed] [Google Scholar]
  • 4.Lee C, Kerrigan CL, Tellado JM. Altered neutrophil function following reperfusion of an ischemic myocutaneous flap. Plast Reconstr Surg. 1992;89:916–923. doi: 10.1097/00006534-199205000-00023. [DOI] [PubMed] [Google Scholar]
  • 5.Ichikaea F, Miyazaki S. New biodefence strategies by neutrophils. Arch Immunol Ther Exp. 2005;53:226. [PubMed] [Google Scholar]
  • 6.Kelly KJ, Williams WW, Jr, Colvin RB. Intercellular adhesion molecule- 1 -deficient mice are protected against ischemic renal injury. J Clin Invert. 1996;97:1056–1063. doi: 10.1172/JCI118498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Sener G, Sehirli O, Velioglu-Ogünç A. Montelukast protects against renal ischemia/reperfusion injury in rats. Pharmacol Res. 2006;54:65–71. doi: 10.1016/j.phrs.2006.02.007. [DOI] [PubMed] [Google Scholar]
  • 8.Suzuki S, Miyachi Y, Niwa Y, Issihiki N. Significance of reactive oxygen species in distal flap necrosis and its salvage with liposomal SOD. Br J Plast Surg. 1989;42:559–564. doi: 10.1016/0007-1226(89)90045-3. [DOI] [PubMed] [Google Scholar]
  • 9.Akamatsu J, Ueda K, Tajima S, Nozawa M. Sulfatide elongates dorsal skin flap survival in rats. J Surg Res. 2000;92:36–39. doi: 10.1006/jsre.2000.5819. [DOI] [PubMed] [Google Scholar]
  • 10.Törkvist L, Månsson P, Raud J. Role of CD18-dependent neutrophil recruitment in skin and intestinal wound healing. Eur Surg Res. 2001;33:249–254. doi: 10.1159/000049714. [DOI] [PubMed] [Google Scholar]
  • 11.Vedder NB, Bucky LP, Richey NL. Improved survival rates of random flaps in rabbits with a monoclonal antibody that blocks leukocyte adherence. Plast Reconstr Surg. 1994;93:1035–1040. doi: 10.1097/00006534-199404001-00020. [DOI] [PubMed] [Google Scholar]
  • 12.Wenzel SE. Arachidonic acid metabolites: Mediators of inflammation in asthma. Pharmaco-therapy. 1997;17:3S–12S. [PubMed] [Google Scholar]
  • 13.Sener G, Kabasakal L, Cetinel S. Leukotriene receptor blocker montelukast protects against burn-induced oxidative injury of the skin and remote organs. Burns. 2005;31:587–596. doi: 10.1016/j.burns.2005.01.012. [DOI] [PubMed] [Google Scholar]
  • 14.World Medical Association World Medical Association Statement on Animal Use in Biomedical Research. http://www.wma.net/e/policy/al8.htm Accessed November 2, 2007.
  • 15.Khouri RK, Angel MF, Edstrom LE. Standardizing the dorsal rat flap. Surg Forum. 1986;37:590–594. [Google Scholar]
  • 16.Aydogan H, Gurlek A, Parlakpinar H. Beneficial effects of caffeic acid phenethyl ester (CAPE) on the ischaemia-reperfusion injury in rat skin flaps. J Plast Reconstr Aesthet Surg. 2007;60:563–568. doi: 10.1016/j.bjps.2006.01.030. [DOI] [PubMed] [Google Scholar]
  • 17.Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: Estimation of neutrophil content with an enzyme marker. J Invest Dermatol. 1982;78:206–209. doi: 10.1111/1523-1747.ep12506462. [DOI] [PubMed] [Google Scholar]
  • 18.Akan M, Cakir B, Misirlioglu A. Effects of clopidogrel and high dose aspirin on survival of skin flaps in rats. Scand J Plast Reconstr Surg Hand Surg. 2005;39:7–10. doi: 10.1080/02844310410017951. [DOI] [PubMed] [Google Scholar]
  • 19.Campbell SP, Moss ML, Hugo NE. When does a random flap die? Plast Reconstr Surg. 1992;89:718–721. doi: 10.1097/00006534-199204000-00023. [DOI] [PubMed] [Google Scholar]
  • 20.Atabey A, Im MJ, Akgur FM. The effect of cobalt chloride on skin flap survival. Br J Plast Surg. 1996;49:321–324. doi: 10.1016/s0007-1226(96)90164-2. [DOI] [PubMed] [Google Scholar]
  • 21.Bilgin-Karabulut A, Ademoglu E, Aydin I. Protective effects of vitamins A and E pre-treatment in venous ischemia/reperfusion injury. J Reconstr Microsurg. 2001;17:425–429. doi: 10.1055/s-2001-16356. [DOI] [PubMed] [Google Scholar]
  • 22.Kawabata H, Knight KR, Coe SA. Experience with calcium antagonists nitrendipine, diltiazem, and verapamil and beta 2-agonist salbutamol in salvaging ischemic skin flaps in rabbits. Microsurgery. 1991;12:160–163. doi: 10.1002/micr.1920120303. [DOI] [PubMed] [Google Scholar]
  • 23.Kiang JG, Tsen KT. Biology of hypoxia. Chin J Physiol. 2006;49:223–233. [PubMed] [Google Scholar]
  • 24.Krysztopik RJ, Bentley FR, Spain DA. Free radical scavenging by lazaroids improves renal blood flow during sepsis. Surgery. 1996;120:657–662. doi: 10.1016/s0039-6060(96)80013-4. [DOI] [PubMed] [Google Scholar]
  • 25.Takamatsu Y, Shimada K, Chijiiwa K. Role of leukotriens on hepatic ischemia reperfusion injury in rats. J Surg Res. 2004;119:14–20. doi: 10.1016/j.jss.2003.07.004. [DOI] [PubMed] [Google Scholar]
  • 26.Baba T, Black KL, Ikezaki K. Intracaratoid infusion of leukotriene C4 selectively increases blood-brain barrier permeability after focal ischemia in rats. J Cereb Blood Flow Metab. 1991;11:638–643. doi: 10.1038/jcbfm.1991.115. [DOI] [PubMed] [Google Scholar]
  • 27.Yu GL, Wei EQ, Zhang SH. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. Pharmacology. 2005;73:31–40. doi: 10.1159/000081072. [DOI] [PubMed] [Google Scholar]
  • 28.Zhang W -P, Wei E-Q, Mei R-H. Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on focal cerebral ischemia in rats. Acta Pharmacol Sin. 2002;23:871–877. [PubMed] [Google Scholar]
  • 29.Zeiger RS, Bird SR, Kaplan MS. Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: A randomized controlled trial. Am J Med. 2005;118:649–657. doi: 10.1016/j.amjmed.2005.03.003. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES